Viatris Inc.
VTRS Healthcare Drug Manufacturers Specialty & Generic
Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024. In the quarter to June 2026, revenue grew 4.88%, EPS fell 2,464.1%, free cash flow grew 101.1% and total debt fell 18.1%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for five consecutive years.
Follow VTRS
Viatris Inc. (VTRS) Free cash flow margin
Viatris Inc.'s free cash flow margin over the twelve months to 30 June 2026 was 12.8%, down 0.7 percentage points from fiscal 2025 (13.6%). Over the past ten years it has ranged from 4.63% (fiscal 2020) to 30.3% (fiscal 2024); the current reading is higher than 64% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 0.00% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 13.6% | (16.74) |
| FY2024 | 30.3% | 12.13 |
| FY2023 | 18.2% | 2.37 |
| FY2022 | 15.8% | 1.68 |
| FY2021 | 14.1% | 9.49 |
| FY2020 | 4.63% | (7.77) |
| FY2019 | 12.4% | 2.12 |
| FY2018 | 10.3% | (0.26) |
| FY2017 | 10.5% | (1.17) |
| FY2016 | 11.7% | (0.37) |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| UTHR United Therapeutics Corporation compare | 34.7% |
| NBIX Neurocrine Biosciences, Inc. compare | 25.8% |
| TAK Takeda Pharmaceutical Co. compare | 24.7% |
| ZTS Zoetis Inc. compare | 24.4% |
| VTRS Viatris Inc. | 12.8% |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 8.09% |
| ELAN Elanco Animal Health Incorporated compare | 7.55% |
| RDY Dr. Reddy's Laboratories Ltd compare | 4.05% |
| HLN Haleon PLC Sponsored ADR compare | 0.00% |
| Drug Manufacturers Specialty & Generic industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on VTRS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement